With friends like this,...Mackie just got a nice chunk of money from TH shareholders for the privilege of leading a disastrous offering which has seriously undercut investor confidence in TH management and board and totally blown the share price up. In return, the Mackie analyst values the NASH opportunity like a phase I asset. I suppose the one thing we can say about TH's relationships with analysts are they are very consistent - consistently bad that is. I am sure you all are like me in marveling over how bad it has been on the analyst front. I don't blame the company for all of the issues over the years but something is clearly way out of bounds here. Does anyone know of any other company that has had such miserable experiences with analysts than TH???
As I have said, the company has actually made a ton of good decisions in recent years and the gambit on NASH was something they should be celebrated for given the FDA has approved of their pahse III trial. Should not analysts be amazed that the company pulled this off and therefore inclined to think positively about the company's NASH prospects? That is the normal situation. How is it that TH is excluded from such good treatment? It make no sense whatsoever. It is a 5 standard deviation event. It is just flat out unexplainable.
I am not sure what else is needed to convince TH's management and board that some really big changes in how they approach things are needed. Hopefully, we will soon see some evidence of dramatic improvements in how the company interacts with analysts and the market generally because this is an extreme situation that needs immediate repair.
But I am so glad TH choose the cheapest option to do their odious offering (sarcasm alert).